Şunu aradınız:: meningitidis (İngilizce - Estonca)

neisseria meningitidis group c (menc):
neisseria meningitidisgrupp c (menc):

detection of neisseria meningitidis antigen in csf
neisseria meningitidis’e antigeeni tuvastamine tserebrospinaalvedelikus;

meningoccocal disease, invasive (neisseria meningitidis)
meningokokk-tekkene invasiivne haigus (neisseria meningitidis)

prophylaxis of invasive infections due to neisseria meningitidis
5 ml 2 x päevas

to prevent infections due to the bacterium neisseria meningitidis
bakteri neisseria meningitidis poolt põhjustatavate nakkuste ennetamine

detection of n. meningitidis antigen from normally sterile site
meningitidis'e kindlaks tegemine tavapäraselt steriilses proovis

detection of n. meningitidis nucleic acid from normally sterile site
meningitidis'e nukleiinhappe kindlaks tegemine tavapäraselt steriilses proovis

recombinant neisseria meningitidis group b nada protein 1, 2, 3
rekombinantne b-grupi neisseria meningitidis'e nada-valk 1, 2, 3

recombinant neisseria meningitidis group b nhba/nada/fhbp proteins
rekombinantne b-grupi neisseria meningitidis'e nhba-/nada-/fhbp-valke

recombinant neisseria meningitidis group b nhba fusion protein 1, 2, 3
rekombinantne b-grupi neisseria meningitidis'e nhba-fusioonvalk 1, 2, 3

neisseria gonorrhoeae neisseria meningitidis non-species-related breakpoints *
neisseria gonorrhoeae neisseria meningitides liikidega mitteseotud piirväärtused *

isolation of neisseria meningitidis from a normally sterile site, including purpuric skin lesions
neisseria meningitidis’e eraldamine tavapäraselt steriilsest proovist, kaasa arvatud veritsevatelt nahakahjustustelt;

menitorix will only confer protection against haemophilus influenzae type b and neisseria meningitidis group c.
menitorix tagab kaitse ainult haemophilus influenzae tüüp b ja neisseria meningitidis c- grupi vastu.

7.5 µg of prp from haemophilus influenzae type b as prp-ompc 125 µg of neisseria meningitidis ompc
7,5 g haemophilus influenzae tüüp b prp prp-ompc-na 125 g neisseria meningitidis ompc

bexsero contains four proteins which are found on the surfaces of cells of the n. meningitidis group b bacterium.
bexsero sisaldab bakteri n. meningitidis b-rühma bakterite rakkude nelja pinnavalku.

neisseria meningitidis ompc (outer membrane protein complex of the b11 strain of neisseria meningitidis subgroup b)
neisseria meningitidis ompc (neisseria meningitidis alagrupp b b11 tüve välismembraani valgukompleks)

bexsero is given to individuals from 2 months of age and older to help protect against disease caused by the neisseria meningitidis group b bacteria.
bexserot manustatakse 2 kuu vanustele ja vanematele isikutele kaitseks haiguse eest, mida põhjustavad b-grupi neisseria meningitidis’e bakterid.

“neisseria meningitidis" types a, c, w-135 and y bacteria can cause serious illnesses such as
neisseria meningitidis’e tüübid a, c, w-135 ja y võivad põhjustada selliseid raskeid haigusi nagu:

at least two weeks before starting soliris treatment, patients must be vaccinated against meningitis caused by the bacterium neisseria meningitidis and revaccinated according to current guidelines.
patsiendid tuleb vähemalt kaks nädalat enne solirisega ravi alustamist vaktsineerida meningiidi vastu, mida põhjustab bakter neisseria meningitidis, ning revaktsineerida vastavalt kehtivatele suunistele.

because of an increased risk of meningitis, soliris should not be given to people who are infected with neisseria meningitidis, or who have not been vaccinated against this bacterium.
suureneva meningiidiohu tõttu ei tohi solirist manustada inimestele, kellel on neisseria meningitidis' e nakkus või kes ei ole selle bakteri vastu vaktsineeritud.